David Thompson
Corporate Officer/Principal chez INOZYME PHARMA, INC.
Postes actifs de David Thompson
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| INOZYME PHARMA, INC. | Corporate Officer/Principal | 01/07/2021 | - |
Historique de carrière de David Thompson
Anciens postes connus de David Thompson
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| INOZYME PHARMA, INC. | Directeur Technique/Scientifique/R&D | 01/04/2018 | 13/10/2020 |
Azure Biotech, Inc.
 Azure Biotech, Inc. BiotechnologyHealth Technology Azure Biotech, Inc. is a private biotechnology company that is developing an alternative product to address the many drawbacks of current therapies for vulvovaginal atrophy (VVA). The company is based in New York, NY. The company has the exclusive worldwide rights to all topical formulations of lasofoxifene, a selective estrogen receptor modulator (SERM). Azure plans to rapidly build upon the extensive safety and efficacy data already available from clinical trials previously completed with an oral formulation in more than 15,000 women. The company was founded by David Thompson. | Fondateur | - | - |
| President | - | - |
Formation de David Thompson
| The University of Montana | Graduate Degree |
| University of Connecticut | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
Opérationnelle
| Graduate Degree | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INOZYME PHARMA, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Azure Biotech, Inc.
Azure Biotech, Inc. BiotechnologyHealth Technology Azure Biotech, Inc. is a private biotechnology company that is developing an alternative product to address the many drawbacks of current therapies for vulvovaginal atrophy (VVA). The company is based in New York, NY. The company has the exclusive worldwide rights to all topical formulations of lasofoxifene, a selective estrogen receptor modulator (SERM). Azure plans to rapidly build upon the extensive safety and efficacy data already available from clinical trials previously completed with an oral formulation in more than 15,000 women. The company was founded by David Thompson. | Health Technology |
- Bourse
- Insiders
- David Thompson
- Expérience
